Developer docs
API playgroundTry for free, no card

Search company profiles

Eli Lilly and Company

Full company profile

uuid02m88az

Namestring
Eli Lilly and Company
Legal namestring
Eli Lilly and Company
Websiteurl
lillyindia.co.in
Company typeenum
Public
Founded yearint
1876
Descriptiontext

Eli Lilly and Company is a global pharmaceutical corporation founded in 1876 in Indianapolis, Indiana, USA, and publicly traded on the New York Stock Exchange under ticker LLY. The company is described in the source data as one of the world's largest pharmaceutical companies, engaged in the discovery, research, scientific development, manufacturing, and commercialization of prescription medicines across multiple therapeutic areas. Its stated functional purpose is the creation of medicines that address treatment gaps across various disease areas, with patient safety and adverse event reporting surfaced as explicit operational priorities.

The company operates internationally through wholly-owned regional subsidiaries, including Lilly India, which handles pharmaceutical sales, marketing, and operations in the Indian market. Local operations in India include a dedicated patient-relations contact channel, local leadership, and a structured social-impact program comprising the Lilly Grant Office, Lilly Global Day of Service, and Connecting Hearts Abroad initiatives. Distribution follows regulated pharmaceutical supply chains spanning distributors, pharmacies, hospitals, and healthcare providers, with marketing of prescription medicines conducted within regulatory frameworks governing drug promotion.

Revenue mechanics are driven by sales of prescription pharmaceutical products across global markets, with pricing set under regulated frameworks that vary by market, payer, and patient-assistance program. The source data does not disclose specific revenue figures, pricing tiers, or contract structures. End customers are patients worldwide receiving pharmaceutical treatment, served via healthcare providers and payers; no named customer logos, channel partners, or segment-level revenue splits are disclosed in the provided input.

Short descriptiontext

Eli Lilly and Company is a global pharmaceutical corporation founded in 1876, headquartered in Indianapolis, Indiana, and listed on NYSE as LLY. It discovers, develops, manufactures, and commercializes prescription medicines for patients worldwide through subsidiaries including Lilly India.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersGurugram, India
HQ citystring
Gurugram
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
pharmaceutical medicines, drug development, prescription drugs, therapeutic research, biopharmaceutical manufacturing
Industry2 codes
1Immunology & Inflammation Pharmaceuticals
CodeHLAIAAADPrimaryYes
2Biologic API/Drug Substance Manufacturing Services
CodeHLAAAKAAPrimaryNo
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceuticals
Social media profiles1 record
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Eli Lilly and Company is a global pharmaceutical corporation that develops, manufactures, and distributes prescription medicines across multiple therapeutic areas. Founded in 1876 and headquartered in Indianapolis, Indiana, the company operates internationally through wholly-owned subsidiaries such as Lilly India, focusing on creating medicines that make life better for people around the world through scientific discovery combined with patient care.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Eli Lilly and Company is a global pharmaceutical company that creates medicines to improve lives. The company operates across multiple therapeutic areas including discovery, research, and scientific development of medicines, with a focus on patient safety. The India operations cover corporate responsibility, social impact initiatives including Lilly Grant Office, Lilly Global Day of Service, and Connecting Hearts Abroad programs.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Novo Nordisk
TypeDirect peer
Description

Global pharmaceutical company with leadership in diabetes and obesity care (GLP-1 franchise), directly competing with Eli Lilly's metabolic disease portfolio including Mounjaro and Zepbound.

2Pfizer
TypeDirect peer
Description

One of the world's largest pharmaceutical companies with a similarly diversified portfolio across multiple therapeutic areas, competing directly with Eli Lilly in oncology, vaccines, and primary care.

3Merck & Co.
TypeDirect peer
Description

Major global pharmaceutical company with oncology and vaccine franchises, competing with Eli Lilly in oncology and other therapeutic areas.

4Roche
TypeDirect peer
Description

Swiss-headquartered global pharmaceutical leader with strong oncology and diagnostics presence, directly competing with Eli Lilly in oncology and other therapeutic categories.

5Novartis
TypeDirect peer
Description

Global pharmaceutical company with diversified portfolio across oncology, cardiovascular, and immunology, directly competing with Eli Lilly across multiple therapeutic areas.

6Johnson & Johnson
TypeDirect peer
Description

Diversified healthcare giant with a major pharmaceutical segment (Janssen) competing with Eli Lilly in oncology, immunology, and neuroscience.

7AbbVie
TypeDirect peer
Description

Global pharmaceutical company with strong immunology and oncology franchises, competing with Eli Lilly in immunology and other specialty therapeutic areas.

8Sanofi
TypeDirect peer
Description

European pharmaceutical major with diabetes, immunology, and rare disease franchises, directly competing with Eli Lilly in several therapeutic categories.

9AstraZeneca
TypeDirect peer
Description

Global biopharmaceutical company with oncology, cardiovascular, and respiratory franchises, competing with Eli Lilly across multiple therapeutic areas.

10GSK
TypeDirect peer
Description

British multinational pharmaceutical company with HIV, respiratory, and vaccines portfolios, competing with Eli Lilly in respiratory and specialty medicine.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eli Lilly and Company

Pharmaceuticalslillyindia.co.in

Eli Lilly and Company is a global pharmaceutical corporation founded in 1876, headquartered in Indianapolis, Indiana, and listed on NYSE as LLY. It discovers, develops, manufactures, and commercializes prescription medicines for patients worldwide through subsidiaries including Lilly India.

What Eli Lilly and Company does

Eli Lilly and Company is a global pharmaceutical corporation founded in 1876 in Indianapolis, Indiana, USA, and publicly traded on the New York Stock Exchange under ticker LLY. The company is described in the source data as one of the world's largest pharmaceutical companies, engaged in the discovery, research, scientific development, manufacturing, and commercialization of prescription medicines across multiple therapeutic areas. Its stated functional purpose is the creation of medicines that address treatment gaps across various disease areas, with patient safety and adverse event reporting surfaced as explicit operational priorities.

The company operates internationally through wholly-owned regional subsidiaries, including Lilly India, which handles pharmaceutical sales, marketing, and operations in the Indian market. Local operations in India include a dedicated patient-relations contact channel, local leadership, and a structured social-impact program comprising the Lilly Grant Office, Lilly Global Day of Service, and Connecting Hearts Abroad initiatives. Distribution follows regulated pharmaceutical supply chains spanning distributors, pharmacies, hospitals, and healthcare providers, with marketing of prescription medicines conducted within regulatory frameworks governing drug promotion.

Revenue mechanics are driven by sales of prescription pharmaceutical products across global markets, with pricing set under regulated frameworks that vary by market, payer, and patient-assistance program. The source data does not disclose specific revenue figures, pricing tiers, or contract structures. End customers are patients worldwide receiving pharmaceutical treatment, served via healthcare providers and payers; no named customer logos, channel partners, or segment-level revenue splits are disclosed in the provided input.

Eli Lilly and Company firmographics

Firmographics
Name
Eli Lilly and Company
Legal name
Eli Lilly and Company
Website
https://lillyindia.co.in
Company type
Public
Founded year
1876
Operating status
Operating
Short description
Eli Lilly and Company is a global pharmaceutical corporation founded in 1876, headquartered in Indianapolis, Indiana, and listed on NYSE as LLY. It discovers, develops, manufactures, and commercializes prescription medicines for patients worldwide through subsidiaries including Lilly India.
Ownership category
akta.pro rank

Eli Lilly and Company industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
akta.pro secondary industry
Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)

Keywords

  • Pharmaceutical medicines
  • Drug development
  • Prescription drugs
  • Therapeutic research
  • Biopharmaceutical manufacturing

Where Eli Lilly and Company is headquartered

Location

Headquarters

HQ city
Gurugram
HQ country
India
HQ region
Asia

Markets served

Eli Lilly and Company business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Eli Lilly and Company product offering

Product offering

Core offering

Eli Lilly and Company is a global pharmaceutical corporation that develops, manufactures, and distributes prescription medicines across multiple therapeutic areas. Founded in 1876 and headquartered in Indianapolis, Indiana, the company operates internationally through wholly-owned subsidiaries such as Lilly India, focusing on creating medicines that make life better for people around the world through scientific discovery combined with patient care.

Product overview

Eli Lilly and Company is a global pharmaceutical company that creates medicines to improve lives. The company operates across multiple therapeutic areas including discovery, research, and scientific development of medicines, with a focus on patient safety. The India operations cover corporate responsibility, social impact initiatives including Lilly Grant Office, Lilly Global Day of Service, and Connecting Hearts Abroad programs.

Differentiator

Problem solved

Functional benefit

Companies that use Eli Lilly and Company

Customer profile

Segments1 record

Ideal customer profiles2 records

Eli Lilly and Company technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Eli Lilly and Company partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights3 records

Eli Lilly and Company competitors and assessment

Company assessment

Direct peers

  • Novo Nordisk: Global pharmaceutical company with leadership in diabetes and obesity care (GLP-1 franchise), directly competing with Eli Lilly's metabolic disease portfolio including Mounjaro and Zepbound.
  • Pfizer: One of the world's largest pharmaceutical companies with a similarly diversified portfolio across multiple therapeutic areas, competing directly with Eli Lilly in oncology, vaccines, and primary care.
  • Merck & Co. Major global pharmaceutical company with oncology and vaccine franchises, competing with Eli Lilly in oncology and other therapeutic areas.
  • Roche: Swiss-headquartered global pharmaceutical leader with strong oncology and diagnostics presence, directly competing with Eli Lilly in oncology and other therapeutic categories.
  • Novartis: Global pharmaceutical company with diversified portfolio across oncology, cardiovascular, and immunology, directly competing with Eli Lilly across multiple therapeutic areas.
  • Johnson & Johnson: Diversified healthcare giant with a major pharmaceutical segment (Janssen) competing with Eli Lilly in oncology, immunology, and neuroscience.
  • AbbVie: Global pharmaceutical company with strong immunology and oncology franchises, competing with Eli Lilly in immunology and other specialty therapeutic areas.
  • Sanofi: European pharmaceutical major with diabetes, immunology, and rare disease franchises, directly competing with Eli Lilly in several therapeutic categories.
  • AstraZeneca: Global biopharmaceutical company with oncology, cardiovascular, and respiratory franchises, competing with Eli Lilly across multiple therapeutic areas.
  • GSK: British multinational pharmaceutical company with HIV, respiratory, and vaccines portfolios, competing with Eli Lilly in respiratory and specialty medicine.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

Eli Lilly and Company social profiles

Digital presence

Eli Lilly and Company financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eli Lilly and Company leadership team

Management profile

Number of profiles

Eli Lilly and Company subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Eli Lilly and Company funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eli Lilly and Company M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eli Lilly and Company

What does Eli Lilly and Company do?

Eli Lilly and Company is a global pharmaceutical corporation that develops, manufactures, and distributes prescription medicines across multiple therapeutic areas. Founded in 1876 and headquartered in Indianapolis, Indiana, the company operates internationally through wholly-owned subsidiaries such as Lilly India, focusing on creating medicines that make life better for people around the world through scientific discovery combined with patient care.

Is Eli Lilly and Company a public or private company?

Eli Lilly and Company is a public company. It is classified as public and is currently operating.

When was Eli Lilly and Company founded?

Eli Lilly and Company was founded in 1876.

Where is Eli Lilly and Company based?

Eli Lilly and Company is headquartered in Gurugram, India, in the Asia region.

Who are Eli Lilly and Company's main competitors?

Direct peers on record are Novo Nordisk, Pfizer, Merck & Co., Roche, Novartis, Johnson & Johnson, AbbVie, Sanofi, AstraZeneca and GSK.

Does Eli Lilly and Company have an API?

No public API is recorded for Eli Lilly and Company.

What industry is Eli Lilly and Company in?

Eli Lilly and Company's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAAAKAA, Biologic API/Drug Substance Manufacturing Services. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireLuma Group Successfully Closes LumaBio Fund I at $410 MillionLuma Group closed its inaugural life sciences fund, LumaBio Fund I, with $410 million in committed capital. The fund has already made its first exit via the acquisition of Vaccine Company by Eli Lilly, valued at up to $1.55 billion. The 15-year vehicle plans to invest early in companies across the life sciences pipeline.ET Edge InsightsConvening India’s Brightest Minds: The Bharat Life Sciences Award Innovation Summit to shape the next chapter of life sciencesLilly India, in partnership with FICCI, is launching the inaugural Bharat Life Sciences Award 2026 Innovation Summit on 1 October 2026 at Vigyan Bhawan, New Delhi, convened with the Office of the Principal Scientific Adviser, DPIIT and Startup India. The event will host three sessions on manufacturing, AI-enabled drug discovery and vaccine platforms, supported by BIRAC, Invest India and several industry bodies.The Times of IndiaConvening India's brightest minds: The Bharat Life Sciences Award’s Innovation Summit to spotlight life sciencesLilly India, in partnership with FICCI, announced the inaugural Bharat Life Sciences Award 2026, a national platform to be held on 1 October 2026 at Vigyan Bhawan, New Delhi. The event will include three thematic sessions on manufacturing, AI-accelerated drug discovery and vaccine platforms, with support from BIRAC, Invest India and several industry bodies.Business StandardConvening India's Brightest Minds: The Bharat Life Sciences Award Innovation Summit to Shape the Next Chapter of Life SciencesLilly India and FICCI are presenting the inaugural Bharat Life Sciences Award (BLSA) 2026, scheduled for October 1, 2026, at Vigyan Bhawan in New Delhi. The event aims to foster collaboration across academia, industry, and government to transition India's life sciences sector from generic manufacturing to innovation-led global leadership. It will feature thematic sessions on manufacturing ecosystems, AI-accelerated drug discovery, and vaccine platforms.The HinduKerala HC allows breast cancer patient to be impleaded in case on 'exorbitant’ prices of medicinesThe Kerala High Court has allowed a breast cancer patient to join an existing legal petition challenging the high prices of the life-saving medication Ribociclib. The court directed the National Cancer Institute and other agencies to evaluate whether Palbociclib, a cheaper alternative suggested by pharmaceutical companies Eli Lilly and Novartis, can serve as a substitute for Ribociclib.Pulse 2.0Amplifica Raises $26 Million Series B To Advance Injectable Hair Regrowth TherapiesAmplifica Holdings Group has raised an oversubscribed $26 million in Series B financing to advance its pipeline of injectable therapies for hair regrowth. The funding, led by Tasso Partners with participation from Eli Lilly and Company, will primarily support the clinical development of product candidates targeting androgenetic alopecia.AijournAmplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying RNA Vaccines for Infectious DiseasesAmplitude Therapeutics and Eli Lilly and Company have entered a strategic research collaboration to develop trans-amplifying RNA (taRNA) vaccine candidates for infectious diseases. Under the agreement, Amplitude will lead taRNA optimization and preclinical research while Lilly retains exclusive rights to further development, manufacturing, and commercialization of the licensed products. The initial programs target high-unmet-need infectious diseases, with Lilly holding options to add up to two additional targets.PR NewswireAmplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying RNA Vaccines for Infectious DiseasesAmplitude Therapeutics and Eli Lilly and Company entered a strategic research collaboration and licensing agreement to develop trans-amplifying RNA (taRNA) vaccine candidates for infectious diseases. Under the deal, Amplitude will lead taRNA optimization and preclinical research while Lilly retains exclusive rights to handle further development, manufacturing, regulatory activities, and commercialization.Third NewsVeeva Vault CRM Gains Global Adoption by Eli Lilly and CompanyOn August 11, 2026, Veeva Systems announced that Eli Lilly and Company has globally adopted its Veeva Vault CRM platform. This strategic partnership leverages artificial intelligence through the "Agentic Commercial" model to enhance healthcare delivery and support sales teams in distributing innovative medicines. The adoption marks a deeper commitment between the two companies to refine commercial offerings within the life sciences sector.Insider Trading & Hedge Fund DataEli Lilly and Company (LLY)’s Weight-Loss Pill Just Won Its First Race in Europe. Novo Nordisk A/S (NVO) Still Has a Head StartEli Lilly's weight-loss pill Foundayo received regulatory approval in the UK, becoming the first country in Europe to clear the drug for both weight management and type 2 diabetes. This development positions Lilly to challenge Novo Nordisk, which holds a significant head start with its Wegovy pill having already secured approvals and generated substantial prescription volumes in the region.